NTY Stock Overview
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Nabriva Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.67 |
| 52 Week High | US$2.42 |
| 52 Week Low | US$0.52 |
| Beta | 1.64 |
| 1 Month Change | 0% |
| 3 Month Change | -1.48% |
| 1 Year Change | -69.77% |
| 3 Year Change | -99.29% |
| 5 Year Change | n/a |
| Change since IPO | -99.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| NTY | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 1.8% |
| 1Y | -69.8% | -27.7% | 2.2% |
Return vs Industry: NTY underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: NTY underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| NTY volatility | |
|---|---|
| NTY Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NTY's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NTY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 39 | H. Hogan | www.nabriva.com |
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections.
Nabriva Therapeutics plc Fundamentals Summary
| NTY fundamental statistics | |
|---|---|
| Market cap | €1.57m |
| Earnings (TTM) | -€51.34m |
| Revenue (TTM) | €27.56m |
0.1x
P/S Ratio0.0x
P/E RatioIs NTY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTY income statement (TTM) | |
|---|---|
| Revenue | US$29.56m |
| Cost of Revenue | US$47.66m |
| Gross Profit | -US$18.11m |
| Other Expenses | US$36.95m |
| Earnings | -US$55.05m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -17.04 |
| Gross Margin | -61.26% |
| Net Profit Margin | -186.26% |
| Debt/Equity Ratio | -3.3% |
How did NTY perform over the long term?
See historical performance and comparison